Article Text

Download PDFPDF

897-C TROCEPT tumor-specific targeting and replication enables in-tumor production of immune checkpoint inhibitors following intravenous delivery
  1. Rahul C Khanolkar1,
  2. James A Davies1,
  3. Alexander T Baker1,
  4. Thomas A Webb1,
  5. Alicia Teijeira-Crespo2,
  6. Hanni K Uusi-Kerttula2,
  7. Lucy M Williams1,
  8. Samantha L Moore1,
  9. Johanne M Pentier1,
  10. Bent K Jakobsen1,
  11. Alan L Parker1,2,
  12. David K Cole1,2,
  13. Andrew B Gerry1 and
  14. David Krige1
  1. 1Accession Therapeutics Ltd, Oxford, UK
  2. 2Cardiff University, Cardiff, UK
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background TROCEPT is a novel tumor-selective oncolytic adenovirus type 5 engineered to remove all natural tissue tropisms. This engineering addresses the main limitation of other viral therapies which infect normal tissues and are rapidly removed by the liver, thereby limiting tumour bioavailability. TROCEPT has been further engineered to specifically bind to αvβ6 integrin which is expressed at high frequency in the majority of epithelial cell derived cancers. In addition, the TROCEPT platform can encode transgenes which enables in-tumor production of powerful therapeutic drugs. The lead programme, TROCEPT-01, encodes a fully human, full length immune checkpoint inhibitor (ICI) antibody. TROCEPT-01 is currently undergoing IND-enabling studies and is expected to enter First in Human studies in 2024 in multiple solid tumor indications.

Methods TROCEPT-01’s tumor selectivity was investigated in both in vitro and in vivo studies.

Results Here we demonstrate in vitro that both viral replication and oncolytic cell death following infection with TROCEPT-01 is selective for tumor cells compared to a panel of normal human primary cells. In addition, following intravenous delivery in in vivo models comprising human αvβ6 integrin-positive tumors engrafted in immune-deficient mice, we demonstrate virus delivery and transgene expression in the tumor.

Conclusions TROCEPT-01’s tumor selective transgene expression and in-tumor production of ICIs enables high local drug concentration in the tumor, potentially reducing systemic toxicity and increasing efficacy. Additionally, several pre-clinical studies have demonstrated that oncolytic viruses can induce anti-viral immunity against infected tumor cells, recruiting cytotoxic T cells and other pro-inflammatory cell types. Thus, TROCEPT delivery of ICIs has the potential to generate a synergistic effect, first attracting and activating T cells, and then enabling tumor-localized production of ICIs to high concentrations to boost anti-tumor T cell responses and increase response rates. TROCEPT has the potential for the delivery of a variety of new and powerful therapeutic drugs to tumors. TROCEPT-01 is currently undergoing IND-enabling studies and is expected to enter First in Human studies in 2024 in multiple solid tumor indications.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.